For Immediate Release

HOSPIRA ANNOUNCES IMPORTANT SAFETY INFORMATION REGARDING CARPUJECT SYRINGE SYSTEM AND THE POTENTIAL FOR OVERFILL

-- Company requests healthcare professionals visually inspect and confirm the fill volume prior to administration --

LAKE FOREST, Ill., May 18, 2012 – Hospira, Inc. (NYSE: HSP) announced today that it is notifying healthcare professionals regarding the potential for overfill in the pre-filled Carpuject™ Syringe System, as some syringes may contain more medication than is stated on the label. The notice applies to Carpuject syringes and the 2mL iSecure™ presentations of midazolam and ondansetron within expiration, which includes the following 15 drugs, all of which were manufactured between June 2010 and February 2012.

- Fentanyl Citrate
- Heparin Sodium
- HYDROMorphone HCl
- Morphine Sulfate
- Demerol™ (meperidine HCl)
- Labetalol Hydrochloride
- Metoprolol Tartrate
- Diazepam
- Ketorolac Tromethamine
- Lorazepam
- Midazolam
- Naloxone Hydrochloride
- Ondansetron
- Sodium Chloride
- Heparin Lock Flush Solution

Hospira has not received any reports of adverse events related to this issue to date. The company has identified the root cause to be due to a manufacturing issue in the filling equipment and has implemented corrective actions to prevent further occurrence.

At this time, although it is believed that the potential for overfill occurrence (where the syringe contains more than the intended fill volume) is low, medication overfill has been reported. If administered to patients, overfilled syringes can lead to accidental overdose, which could have significant impact to patients and result in life-threatening consequences.
HOSPIRA ANNOUNCES IMPORTANT SAFETY INFORMATION REGARDING CARPUJECT SYRINGE SYSTEM AND THE POTENTIAL FOR OVERFILL

PAGE 2

Action Required for Healthcare Professionals

Before administering the medications contained in the pre-filled Carpuject syringes, healthcare providers should visually inspect the fill volume in the syringe and verify that it matches the labeled volume. For photos of the Carpuject syringe and a list of potentially impacted products and lots, please click here.

On inspection, if an overfilled Carpuject syringe is detected, the unit should not be used. The clinician should report the incident to Hospira as a complaint, including specific product information and lot number, and return the product to Hospira for evaluation.

For the recently recalled lots of Morphine Sulfate Injection, USP, 4 mg/mL, or Hydromorphone Hydrochloride Injection 1 mg/1mL, healthcare professionals are reminded to follow the instructions in the relevant recall notices.

For medical inquiries, please contact Hospira Medical Communications at 1-800-615-0187 (24 hours a day, seven days a week) or email Medcom@hospira.com. To report product complaints, such as an overfilled Carpuject or adverse events, call 1-800-441-4100 or email productcomplaintspp@hospira.com.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

- Online: www.fda.gov/medwatch/report.htm
- Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.
- Fax: 1-800-FDA-0178
This notice is being provided with the knowledge of the U.S. Food & Drug Administration (FDA).

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira’s results of operations; projections of certain charges, expenses, and cash flow; and other statements regarding Hospira’s goals, plans and strategy. Hospira cautions that these forward-looking statements are subject to risks and uncertainties, including adequate and sustained progress on the company's quality initiatives, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological, manufacturing supply, quality and other factors that may affect Hospira’s operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q, filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

###

Media
(224) 212-2357

Financial Community
(224) 212-2711